Oncology

MDx (Molecular Diagnostics) is increasingly impacting a number of areas of cancer care delivery including diagnosis, prognosis, in predicting response to particular therapies, and in minimal residual disease monitoring.

The IntelliGenome team has developed a high-efficiency DNA polymerase-based and thermostable protein-enhanced CRISPR fluorescence detection system, and further developed an ultra-sensitive approach to detect cancer derived cell-free DNA (cfDNA) in blood samples, which is an isolation-free, multiplex recombinase polymerase amplification (RPA)-CRISPR detection assay, and a portable device to read POC test results.